Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PAK4 | O96013 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESRRG | P62508 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 8/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.37 |
| ▸ | RET | P07949 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13221314 | 0.78 | RET (0.44) | RET | |
| SCHEMBL13221456 | 0.74 | MAP3K5 (0.40) | NPC1RAB9AKDM4EMAPTLMNA | |
| SCHEMBL13221325 | 0.74 | GSK3B (0.54) | NPC1RAB9AKDM4E | |
| SCHEMBL13221373 | 0.73 | NPC1 (0.41) | NPC1RAB9AKDM4EMAPTPAK4 | |
| SCHEMBL13221356 | 0.72 | BRD4 (0.42) | KDM4EHPGDLMNA | |
| SCHEMBL5262598 | 0.72 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2RET | |
| SCHEMBL13221136 | 0.71 | MAP4K2 (0.44) | NPC1RAB9AMAPK14RETDYRK1A | |
| SCHEMBL24174416 | 0.71 | PLK4 (0.41) | KDM4EMAPTSMN1; SMN2PAK4RET | |
| SCHEMBL3040349 | 0.71 | AURKA (0.42) | NPC1RAB9AKDM4E | |
| SCHEMBL3045180 | 0.71 | RET (0.49) | KDM4EMAPTHPGDRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | claimed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | claimed |
| JP-2008516973-A | — | — | 2008-05-22 | — | — | JP | claimed |
| EP-1812439-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-08-01 | — | — | EP | claimed |
| WO-2006044687-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-04-27 | — | — | WO | claimed |
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| EP-1812439-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006044687-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060084650-A1 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084650-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | NPC1 4032/4885RAB9A 2122/4885KDM4E 1350/4885 |
| US-20100216765-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | NPC1 4032/4885RAB9A 2122/4885KDM4E 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.